Skip to main content

Search

Neuroscience Research

Neuroscience

We want to reduce the burden, disability and devastation caused by serious neuropsychiatric and neurodegenerative diseases. Our mission is to develop new solutions and innovations that not only improve, but transform, the lives of people living with mental illness. We are committed to improving the way in which mental health disorders are prevented, diagnosed and treated in order to change the lives of people living with mental illness.

One in four of us will be affected by a mental health disorder in our lifetime.[1] We recognise the heartbreak that these conditions can cause for those affected and their loved ones. The burden and impact of mental illness is vast. That’s why we need an on-going dialogue with patients and their carers to enhance our understanding of living with mental health conditions. Because it’s through understanding mental illness from the perspective of those living with these conditions that we’re better able to help.

 

Our track record in neuroscience spans over six decades. Our story began in 1958 when we developed a pioneering schizophrenia therapy, one of the first antipsychotics. That treatment is one of two psychiatric medicines we have developed, both of which are recognised by the World Health Organization as Essential Medicines.[2] Since then, we have researched and offered more than 20 treatments and innovations, which collectively have helped to shape the care of people living with neuropsychiatric disorders.[3]

Our disease areas of focus are Schizophrenia, Major Depressive Disorder (MDD) and Multiple Sclerosis (MS).

 

References

[1]World Health Report. Mental disorders affects one in four people. Available at: https://www.who.int/whr/2001/media_centre/press_release/en/ . Accessed: October 2020.
[2]WHO. Model List of Essential Medicines. Available at:  https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1 Accessed: November 2020.
[3]Janssen. 2019. Psychiatry: Mood Disorders Portfolio. Data on file. PSY/DOF/MAY2019/EMEA001.

CP-346516 | September 2022